Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bird Flu
Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
August 27th, 2007
Carrington Laboratories, Inc. (NASDAQ:CARN) announced its subsidiary DelSite Biotechnologies, Inc. has initiated the animal toxicology studies of its GelVac(TM) nasal powder influenza vaccine, incorporating an H5N1 (bird flu) antigen. The toxicology studies are a critical step during the vaccine development and will assess the vaccine safety in animals. Pending successful results of the toxicology studies and discussion with the antigen supplier, DelSite will file an IND for a phase I human safety study of the GelVac(TM) nasal powder H5N1 vaccine in late 2007. The toxicology studies are being conducted at a well-known contract research organization, using study...
Source: Clinical Trials Week (2007-08-27)
|
